Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Anti-TNF-alpha therapy increases the risk of psoriasis in patients with rheumatoid arthritis

Antitumor necrosis factor (TNF) alpha therapy is commonly used to treat severe rheumatoid arthritis (RA) and has been proven efficacious in psoriatic arthritis, a condition which involves the combined occurrence of psoriasis and inflammatory arthritis. However, the findings of a recent observational cohort study in patients from the British Society for Rheumatology Biologics Register (BSRBR) suggest that anti-TNF-alpha therapy in patients with RA may be associated with an elevated risk of developing psoriasis compared to treatment with traditional disease-modifying antirheumatic drugs (DMARDs). Patients who had received anti-TNF-alpha therapy (n = 9,826) and a comparison cohort treated with DMARDs (n = 2,880 patients) participated in the study. Anti-TNF-alpha therapy included administration of the ...